Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)

Title: Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)

Volume: 6 Issue: 2

Author(s): Phil Skolnick and Anthony S. Basile

Affiliation:

Keywords: Antidepressant, dopamine, serotonin, norepinephrine, biogenic, amines, depression

Abstract: The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors.

Cite this article as:

Skolnick Phil and Basile S. Anthony, Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants), CNS & Neurological Disorders - Drug Targets 2007; 6 (2) . https://dx.doi.org/10.2174/187152707780363285